Acne is a one of the most frequent skin conditions among teenagers and young adults. It is currently managed with topical retinoids and antibiotics, which can present numerous side effects, thus reducing treatment adherence and effectiveness. We evaluated the efficacy and tolerability of a novel dermo-cosmetic cream (α-AZ) in treating mild to moderate acne. Subjects were randomized into three groups: group1 received α-AZ cream, group2 was treated with α-AZ combined with an oral acne treatment routine, and group3 received a topical acne treatment, for 84days. All treated patients underwent a 28-day maintenance period with α-AZ cream. Total acne and post-inflammatory hyperpigmentation (PIH) scoring, quality of life (QoL), and skin tolerance were all evaluated during the treatment and maintenance periods. Acne and PIH lesions significantly decreased in group1 compared to group3 (p < 0.001), with a reduction in acne of 66.52 ± 2.92% in group1 versus 52.55 ± 3.90% in group3. Patients in group1 achieved nearly clear skin by the end of the treatment. α-AZ cream treatment was well tolerated and all participants experienced an enhanced QoL. Participants expressed high satisfaction. Additional enhancements in all groups were noted during the maintenance phase across all clinical parameters. The novel dermo-cosmetic α-AZ cream could serve as a valuable new approach to current treatments for mild and moderate acne. It can be used alone, as a once-daily adjuvant to oral acne treatments, or as part of a maintenance regimen. ISRCTN registry, ISRCTN70142596, registered retrospectively on 11/12/2023.